Payment overview · 2025
General Payments
$398.20
20 reported records · 13 companies
Healthcare provider profile · identity verified
Jackie Lee Stringfellow, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CARROLLTON, GA · NPI 1386625200
Verified facts
What the public records show
CMS Open Payments records show Jackie Lee Stringfellow, M.D. received $398.20 in general payments during 2025 across 20 reported records.
Novartis Pharmaceuticals Corporation accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $77.48 | 19.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.28 | 18.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $58.16 | 14.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.62 | 8.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.85 | 6.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.68 | 6.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.94 | 4.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.27 | 4.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.05 | 4.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.31 | 4.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.87 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.45 | 3.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.24 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.20 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $77.48 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $58.16 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
90 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
58 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
54 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
155 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
206 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 751 | 126 |
| Omeprazole | Omeprazole | 751 | 185 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 749 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 742 | 201 |
| Levothyroxine Sodium | Levothyroxine Sodium | 700 | 149 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 664 | 186 |
| Atorvastatin Calcium | Atorvastatin Calcium | 500 | 133 |
| Gabapentin | Gabapentin | 500 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 497 | 141 |
| Metoprolol Succinate | Metoprolol Succinate | 418 | 105 |
| Losartan Potassium | Losartan Potassium | 390 | 101 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 381 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 356 | 75 |
| Simvastatin | Simvastatin | 352 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 329 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 284 | 69 |
| Furosemide | Furosemide | 273 | 86 |
| Potassium Chloride | Potassium Chloride | 273 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 272 | 63 |
| Sertraline Hcl | Sertraline Hcl | 272 | 73 |
| Lorazepam | Lorazepam | 265 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 73 |
| Clonazepam | Clonazepam | 258 | 33 |
| Metformin Hcl Er | Metformin Hcl | 257 | 63 |
| Lisinopril | Lisinopril | 256 | 68 |
| Trazodone Hcl | Trazodone Hcl | 254 | 53 |
| Tramadol Hcl | Tramadol Hcl | 253 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 58 |
| Glimepiride | Glimepiride | 209 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 207 | 54 |
| Ozempic | Semaglutide | 206 | 35 |
| Meloxicam | Meloxicam | 204 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 202 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 192 | 44 |
| Allopurinol | Allopurinol | 191 | 53 |
| Atenolol | Atenolol | 191 | 38 |
| Famotidine | Famotidine | 184 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 182 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 177 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 174 | 36 |
| Prednisone | Prednisone | 170 | 105 |
| Eliquis | Apixaban | 155 | 38 |
| Mounjaro | Tirzepatide | 155 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 37 |
| Memantine Hcl | Memantine Hcl | 149 | 39 |
| Ondansetron Odt | Ondansetron | 145 | 59 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 142 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 53 |
| Bupropion Xl | Bupropion Hcl | 131 | 33 |
| Carvedilol | Carvedilol | 128 | 31 |
| Montelukast Sodium | Montelukast Sodium | 127 | 29 |
| Nifedipine Er | Nifedipine | 114 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 81 |
| Sucralfate | Sucralfate | 108 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 107 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 23 |
| Amoxicillin | Amoxicillin | 102 | 80 |
| Glipizide | Glipizide | 101 | 28 |
| Temazepam | Temazepam | 101 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 25 |
| Diazepam | Diazepam | 92 | 22 |
| Synthroid | Levothyroxine Sodium | 90 | 17 |
| Triazolam | Triazolam | 90 | 20 |
| Pregabalin | Pregabalin | 89 | 24 |
| Torsemide | Torsemide | 86 | 27 |
| Morphine Sulfate Er | Morphine Sulfate | 84 | suppressed |
| Celecoxib | Celecoxib | 83 | 21 |
| Methadone Hcl | Methadone Hcl | 81 | suppressed |
| Mirtazapine | Mirtazapine | 80 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 23 |
| Alendronate Sodium | Alendronate Sodium | 75 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 74 | 15 |
| Lovastatin | Lovastatin | 73 | 18 |
| Estradiol | Estradiol | 71 | 20 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 71 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 37 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 69 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 68 | 15 |
| Meclizine Hcl | Meclizine Hcl | 67 | 29 |
| Ezetimibe | Ezetimibe | 66 | 21 |
| Warfarin Sodium | Warfarin Sodium | 66 | 11 |
| Zaleplon | Zaleplon | 65 | 24 |
| Levofloxacin | Levofloxacin | 64 | 61 |
| Cefdinir | Cefdinir | 63 | 53 |
| Fluconazole | Fluconazole | 62 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 62 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 61 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 61 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 58 | 58 |
| Ibuprofen | Ibuprofen | 56 | 18 |
| Promethazine Hcl | Promethazine Hcl | 54 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 37 |
| Linzess | Linaclotide | 53 | 14 |
| Baclofen | Baclofen | 51 | 11 |
| Jardiance | Empagliflozin | 51 | 15 |
| Methocarbamol | Methocarbamol | 51 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 15 |
| Aripiprazole | Aripiprazole | 49 | 16 |
| Azithromycin | Azithromycin | 49 | 45 |
| Glipizide Er | Glipizide | 48 | 15 |
| Terazosin Hcl | Terazosin Hcl | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 16 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 25 |
| Testosterone | Testosterone | 44 | suppressed |
| Cephalexin | Cephalexin | 43 | 35 |
| Dexamethasone | Dexamethasone | 43 | 34 |
| Modafinil | Modafinil | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Mupirocin | Mupirocin | 42 | 27 |
| Spironolactone | Spironolactone | 42 | 16 |
| Myrbetriq | Mirabegron | 40 | 12 |
| Topiramate | Topiramate | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 11 |
| Carisoprodol | Carisoprodol | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 21 |
| Megestrol Acetate | Megestrol Acetate | 37 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 15 |
| Finasteride | Finasteride | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Oxycontin | Oxycodone Hcl | 35 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 20 |
| Valacyclovir | Valacyclovir Hcl | 33 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Metformin Hcl | Metformin Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 22 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Budesonide Dr | Budesonide | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 11 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Nystatin | Nystatin | 26 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 26 | suppressed |
| Sulindac | Sulindac | 26 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Klor-Con M10 | Potassium Chloride | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 18 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 16 |
| Nitroglycerin | Nitroglycerin | 18 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Famciclovir | Famciclovir | 16 | 11 |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | 11 |
| Scopolamine | Scopolamine | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Colchicine | Colchicine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Primidone | Primidone | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cabergoline | Cabergoline | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.20 · 20 records | Novartis Pharmaceuticals Corporation | ABRYSVO, AREXVY, Auvelity, COMIRNATY, Cologuard Collection Kit, JARDIANCE, LEQVIO, NURTEC ODT, PREVNAR 20, QULIPTA, REXULTI, SHINGRIX, TZIELD, UBRELVY, VOQUEZNA, Veozah, XIFAXAN, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error